ArticleCancer chemotherapy and pharmacology2023

A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.

Alicja Puszkiel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.